Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.

NCT01655693 is registered in ClinicalTrials.gov with Valerio Therapeutics as lead sponsor.

NCT NCT01655693
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01655693 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Doxorubicin Transdrug™ to Best Standard of Care in Patients With Advanced Hepatocellular Carcinoma. ReLive Study.
Lead sponsor
Valerio Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2012
Completion date
May 31, 2019
Enrollment
397 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular